Sinusoidal Obstruction Syndrome

Clinics in Liver Disease

Volumn 14, Issue 4, 2010, Pages 651-668

  Rubbia Brandt, Laura ^a  

^a Division of Clinical Pathology   (Switzerland)

Author keywords

Chemotherapy; Colorectal liver metastases; Drugs; Hepatic vascular lesions; Hepatotoxicity; Oxaliplatin

Indexed keywords

ALKALOID DERIVATIVE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BEVACIZUMAB; BUSULFAN; CARMUSTINE; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEFIBROTIDE; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; HEPARIN; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; MITOMYCIN; MYELOABLATIVE AGENT; OXALIPLATIN; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR; PROSTAGLANDIN E1; TIOGUANINE; URETHAN; URSODEOXYCHOLIC ACID;

ADVERSE OUTCOME; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DISEASE MODEL; DISEASE SEVERITY; DRUG MEGADOSE; ENDOTHELIUM CELL; HERBAL MEDICINE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER CIRCULATION; LIVER CONGESTION; LIVER FIBROSIS; LIVER HYPERPLASIA; LIVER INJURY; LIVER METASTASIS; LIVER NODULE; LIVER RESECTION; LIVER SINUSOID; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MICROCIRCULATION; MOLECULAR MECHANICS; MYELOABLATIVE CONDITIONING; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POSTOPERATIVE COMPLICATION; RADIOFREQUENCY ABLATION; REVIEW; SINUSOIDAL OBSTRUCTION SYNDROME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; WHOLE BODY RADIATION;

ANIMALS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS;

EID: 78049466375     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.07.009     Document Type: Review

References (78)

1. Willmot F. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 1920, 196:848.
2. Bras G., Jeliffe D.B., Stuart K.L. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 1954, 57:285-300.
3. Stuart K.L., Bras G. Veno-occlusive diseases of the liver. Q J Med 1957, 26:291.
4. Levitsky J., Sorrell M.F. Hepatic complications of hematopoietic cell transplantation. Curr Gastroenterol Rep 2007, 9:60-65.
5. Deleve L.D. Hepatic microvasculature in liver injury. Semin Liver Dis 2007, 27:390-400.
6. Deleve L.D., Valla D., Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009, 49:1729-1764.
7. Shulman H.M., Fisher L.B., Schoch H.G., et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994, 19:1171-1180.
8. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15:460-466.
9. Rubbia-Brandt L., Lauwers G.Y., Wuang H., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010, 56:430-439.
10. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24:4983-4990.
11. Bilchik A.J., Poston G., Curley S.A., et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005, 23:9073-9078.
12. Hubert C., Sempoux C., Horsmans Y., et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?. Liver Int 2007, 1478:938-942.
13. Vollmar B., Menger M.D. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009, 89:1269-1339.
14. McCuskey R.S. Sinusoidal endothelial cells as an early target for hepatic toxicants. Clin Hemorheol Microcirc 2006, 34(1-2):5-10.
15. Crispe I.N. The liver as a lymphoid organ. Annu Rev Immunol 2009, 27:147-163.
16. Yokomori H. New insights into the dynamics of sinusoidal endothelial fenestrae in liver sinusoidal endothelial cells. Med Mol Morphol 2008, 41(1):1-4.
17. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25(3):223-229.
18. Deleve L.D., Wang X., Hu L., et al. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 2004, 287(4):G757-G763.
19. Deleve L.D., Wang X., Guo Y., et al. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008, 48:920-930.
20. Deleve L.D., McCuskey R.S., Wang X., et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999, 29:1779-1791.
21. Murata S., Ohkohchi N., Matsuo R., et al. Platelets promote liver regeneration in early period after hepatectomy in mice. World J Surg 2007, 31:808-816.
22. Deleve L.D., Wang X., Tsai J., et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003, 125:882-890.
23. DeLeve L.D., Wang X., Kanel G.C., et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003, 38:900-908.
24. DeLeve L.D., Ito I., Bethea N.W., et al. Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 2003, 284:G1045-G1052.
25. Schiffer E., Frossard J.L., Rubbia-Brandt L., et al. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol 2009, 99(7):439-446.
26. Laurent A., Nicco C., Chereau C., et al. Controlling tumour growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005, 65:948-956.
27. Alexandre J., Nicco C., Chereau C., et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006, 98:236-244.
28. Zeng H.H., Lu J.F., Wang K. The effect of cisplatin and transplatin on the conformation and association of F-actin. Cell Biol Int 1995, 19:491-497.
29. Iguchi A., Kobayashi R., Yoshida M., et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 2001, 27(11):1173-1180.
30. Brooks S.E.H., Miller C.G., McKenzie K. Acute veno-occlusive diseases of the liver. Arch pathol 1970, 89:507-520.
31. Shulman H.M., Gown A.M., Nugent D.J. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987, 127(3):549-558.
32. Soubrane O., Brouquet A., Zalinski S., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases correlation with post-hepatectomy outcome. Ann Surg 2010, 251:454-460.
33. Lesurtel M., Graf R., Aleil B., et al. Platelet-derived serotonin mediates liver regeneration. Science 2006, 312:104-107.
34. Reshamwala P., Kleiner D.E., Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006, 44:1407-1444.
35. Al-Mukhaizeem K., Rosenberg A., Sherker A.H. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004, 75:225-230.
36. Roskams T., Baptista A., Bianchi L., et al. Histopathology of portal hypertension: a practical guideline. Histopathology 2003, 42:2-13.
37. Wanless I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990, 11:787-797.
38. Wanless I.R., Godwin T.A., Allen F., et al. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine 1980, 59:367-379.
39. Bayraktar U.D., Bayraktar U.D., Bayraktar Y. Hepatic venous outflow obstruction: three similar syndromes. World J Gastroenterol 2007, 13:1912-1927.
40. Ueno S., Tanabe G., Sueyoshi K., et al. Hepatic hemodynamics in a patient with nodular regenerative hyperplasia. Am J Gastroenterol 1996, 91:1012-1015.
41. Naber A.H., Van Haelst U., Yap S.H. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991, 12:94-99.
42. Croquelois A., Blindenbacher A., Terracciano L., et al. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005, 41:487-496.
43. Mendizabal M., Craviotto S., Chen T., et al. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol 2009, 8(4):390-395.
44. Adam R. Colorectal cancer with synchronous liver metastases. Br J Surg 2007, 94:129-131.
45. Mentha G., Majno P.E., Terraz S., et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol 2007, 33:S76-S83.
46. Andres A., Majno P., Morel P., et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol 2008, 15:134-143.
47. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
48. Nordlinger B., Van Cutsem E., Rougier P., et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007, 43:2037-2045.
49. Mentha G., Majno P.E., Andres A., et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006, 93:872-878.
50. Ribero D., Wuang H., Matteo D., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
51. Seium Y., Stupp R., Ruhstaller T., et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 2005, 16:762-766.
52. Rubbia-Brandt L., Giostra E., Brezault C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007, 18:299-304.
53. Arotcarena R., Calès V., Berthelemy P.H., et al. Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy?. Gastroenlerol Clin Biol 2006, 30:1313-1316.
54. Nakano H., Oussoultzoglou E., Rosso E., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008, 247:118-124.
55. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24:2065-2072.
56. Kandutsch S., Klinger M., Hacker S., et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008, 34(11):1231-1236.
57. Tisman G., Macdonald D., Shindell N., et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 2004, 22:3202-3204.
58. Mentha G., Roth A.D., Terraz S., et al. Liver first approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 2008, 25:430-435.
59. Zorzi D., Laurent A., Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007, 94:274-286.
60. Chun Y.S., Laurent A., Maru D., et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009, 10(3):278-286.
61. Floyd J., Sachs B., Perry M.C. Hepatotoxicity of chemotherapy. Semin Oncol 2006, 33:50-67.
62. Slade J.H., Alattar M.L., Fogelman D.R., et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009, 8(4):225-230.
63. Karoui M., Penna C., Amin-Hashem M., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006, 243(1):1-7.
64. Ward J., Guthrie J.A., Boyes S., et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 2008, 26:4304-4310.
65. O'rourke T.R., Welsh F.K., Tekkis P.P., et al. Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol 2009, 35(10):1085-1091.
66. Shulman H.M., Gooley T., Dudley M.D., et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995, 59(7):1015-1022.
67. Abdalla E.K., Hicks M.E., Vauthey J.N. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001, 88:165-175.
68. Abdalla E.K., Barnett C.C., Doherty D., et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002, 137:675-680.
69. Azoulay D., Castaing D., Krissat J., et al. Percutaneous portal vein embolization increases the feasibility and safety of major resection for hepatocellular carcinoma in injured liver. Ann Surg 2000, 232:665-672.
70. Di Stefano D.R., de Baere T., Denys A., et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005, 234:625-630.
71. Mentha G., Terraz S., Morel P., et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 2009, 96(1):95-103.
72. Welsh F.K., Tilney H.S., Tekkis P.P., et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007, 96(7):1037-1042.
73. Solis-Herruzo J.A., Vidal J.V., Colina F., et al. Nodular regenerative hyperplasia of the liver associated with the toxic oil syndrome: report of five cases. Hepatology 1986, 6:687-693.
74. DeLeve L.D., Wang X., Kuhlenkamp J.F., et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996, 23:589-599.
75. Goringe A.P., Brown S., O'callaghan U., et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998, 21(8):829-832.
76. Brouquet A., Benoist S., Julie C., et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009, 145(4):362-371.
77. Klinger M., Eipeldauer S., Hacker S., et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009, 35(5):515-520.
78. Harb R., Xie G., Lutzko C., et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 2009, 137(2):704-712.